Thioguanine Therapy in Essential Thrombocytosis and Polycythemia Vera

Dettagli Bibliografici
Autori principali:	J. Janssen, H. J. Boiten, H. C. T. van Zaanen
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Hematological Oncology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

513 | PROGNOSTIC PREDICTIVE VALUE OF BASELINE 18F‐FDG PET/CT METABOLIC PARAMETERS IN HODGKIN’S LYMPHOMA
di: H. Zhang, et al.
Pubblicazione: (2025)

684 | MECAPEGFILGRASTIM FOR PROPHYLAXIS OF CHEMOTHERAPY‐INDUCED NEUTROPENIA IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: A MULTICENTER PILOT TRIAL
di: J. Wang, et al.
Pubblicazione: (2025)

618 | SEQUENTIAL BTK INHIBITOR THERAPY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: REAL‐WORLD OUTCOMES AND ATTRITION RATES—FINAL REPORT FROM THE ASIA‐PACIFIC REGISTRY
di: H. Cho, et al.
Pubblicazione: (2025)

698 | A NOVEL PROGNOSTIC MODEL FOR PREDICTING DISEASE PROGRESSION AND SURVIVAL IN PRIMARY LARGE B‐CELL LYMPHOMA OF IMMUNE‐PRIVILEGED SITES
di: G. Wang, et al.
Pubblicazione: (2025)

785 | HEMATOLOGIC TOXICITY ANALYSIS OF CAR‐T CELL THERAPY: A RETROSPECTIVE REAL‐WORLD STUDY
di: H. Wang, et al.
Pubblicazione: (2025)

759 | UPDATED OUTCOMES OF P‐GEMD IN TREATMENT‐NAÏVE EARLY‐STAGE NON‐UPPER AERO‐DIGESTIVE TRACT OR ADVANCED‐STAGE EXTRANODAL NK/T CELL LYMPHOMA
di: J. Liang, et al.
Pubblicazione: (2025)

190 | ONCOGENESIS OF ENTEROPATHY‐ASSOCIATED T‐CELL LYMPHOMA: EXTENSIVE PARALLEL CLONAL EVOLUTION AND ITS CLINICAL CONSEQUENCES
di: B. Ylstra, et al.
Pubblicazione: (2025)

123 | UPDATED INTERIM RESULTS OF SONROTOCLAX + DEXAMETHASONE IN PATIENTS WITH T(11;14)‐POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/R MM): AN ALL‐ORAL TREATMENT
di: B. Dhakal, et al.
Pubblicazione: (2025)

CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy
di: J.T. Jutzi, et al.
Pubblicazione: (2025)

713 | CHEMOTHERAPY‐FREE THERAPY WITH RITUXIMAB, LENALIDOMIDE, AND POSELTINIB IN RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A MULTI‐CENTER, PHASE II STUDY
di: D. H. Kim, et al.
Pubblicazione: (2025)

831 | A PHASE 1, MULTICENTER, FIRST‐IN‐HUMAN TRIAL OF GCC2005, AN ALLOGENEIC CAR‐NK CELL THERAPY TARGETING CD5, IN PATIENTS WITH RELAPSED/REFRACTORY NK AND T‐CELL MALIGNANCIES
di: W. S. Kim, et al.
Pubblicazione: (2025)

76 | GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (Glofit‐GemOx) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): 2‐YEAR FOLLOW‐UP OF STARGLO
di: J. S. Abramson, et al.
Pubblicazione: (2025)

550 | PHASE II TRIAL OF ORELABRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA: THE CWCLL‐001 TRIAL
di: Y. Miao, et al.
Pubblicazione: (2025)

317 | MOLECULAR SUBTYPE‐GUIDED R‐MINE+X REGIMEN IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A SINGLE‐ARM, OPEN‐LABEL, MULTICENTER PHASE II STUDY
di: J. Liang, et al.
Pubblicazione: (2025)

Post‐CAR T‐Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B‐Cell Lymphoma
di: Hazim S. Ababneh, et al.
Pubblicazione: (2024)

450 | 5‐5‐5 ABRT (ADAPTIVE BRIDGING RADIATION THERAPY)—ARTIFICIAL INTELLIGENCE ENTERS THE CAR (‐T) IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA: UPDATED ANALYSIS
di: H. Ababneh, et al.
Pubblicazione: (2025)

244 | TISAGENLECLEUCEL VERSUS MOSUNETUZUMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A MATCHING‐ADJUSTED INDIRECT COMPARISON USING 3‐YEAR FOLLOW‐UP DATA
di: N. H. Fowler, et al.
Pubblicazione: (2025)

537 | CLINICAL CHARACTERISTICS OF HEPATITIS B VIRUS REACTIVATION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB: A RETROSPECTIVE MULTICENTRIC STUDY
di: J. Y. Hur, et al.
Pubblicazione: (2025)

12 | IMAGING BIOMARKERS FOR THE DEFINITION OF RESPONSE IN THE GHSG HD18, GHSG HD21 AND LYSA AHL2011 TRIALS FOR ADVANCED‐STAGE HODGKIN LYMPHOMA
di: J. Ferdinandus, et al.
Pubblicazione: (2025)

366 | EVOLVING TREATMENT LANDSCAPE AND OUTCOMES IN ELDERLY HODGKIN LYMPHOMA: A 15‐YEAR MULTICENTER RETROSPECTIVE ANALYSIS FROM CHINA HIGHLIGHTING THE IMPACT OF NOVEL THERAPIES
di: P. Zhao, et al.
Pubblicazione: (2025)

418 | CIRCULATING TUMOR DNA ASSESSMENT IN PATIENTS WITH EARLY‐STAGE CLASSICAL HODGKIN LYMPHOMA TREATED WITH COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB
di: R. C. Lynch, et al.
Pubblicazione: (2025)

206 | SPATIAL AND SINGLE‐CELL MULTI‐OMICS REVEAL MACROPHAGE HETEROGENEITY BETWEEN PRIMARY CNS LYMPHOMA AND DIFFUSE LARGE B‐CELL LYMPHOMA
di: L. Hong, et al.
Pubblicazione: (2025)

Therapy Sequencing in Relapsed/Refractory MCL
di: Eva Giné
Pubblicazione: (2025)

854 | SEQUENCING‐GUIDED CHEMOTHERAPY OPTIMIZATION USING REAL‐TIME EVALUATION IN NEWLY DIAGNOSED DLBCL WITH CIRCULATING TUMOR DNA: SHORTEN‐ctDNA
di: H. J. Cherng, et al.
Pubblicazione: (2025)

439 | ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB + LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
di: Z. Song, et al.
Pubblicazione: (2025)

240 | EPCORITAMAB MONOTHERAPY DEMONSTRATES DEEP AND DURABLE RESPONSES AT 3‐YEAR FOLLOW‐UP IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
di: K. M. Linton, et al.
Pubblicazione: (2025)

490 | MOLECULAR LANDSCAPE OF DISTINCT FOLLICULAR LYMPHOMA HISTOLOGIC GRADES: INSIGHTS FROM GENOMIC AND TRANSCRIPTOME ANALYSES
di: C. Sun, et al.
Pubblicazione: (2025)

816 | FIRST DATA DISCLOSURE FROM PHASE 1B/2 EPCORE NHL‐4: EPCORITAMAB IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
di: W. Zhao, et al.
Pubblicazione: (2025)

62 | A PHASE II TRIAL OF PEMBROLIZUMAB CONCURRENT WITH RADIOTHERAPY FOR FRAIL PATIENTS WITH NEWLY DIAGNOSED EARLY‐STAGE NATURAL KILLER/T‐CELL LYMPHOMA (IELSG50)
di: H. Zhong, et al.
Pubblicazione: (2025)

129 | PEMBROLIZUMAB AND RADIATION THERAPY ALONE AS AN ALTERNATIVE TO TRANSPLANT FOR LOCALIZED FAILURE AFTER CHEMOTHERAPY IN HODGKIN LYMPHOMA: A MULTICENTER PHASE II STUDY
di: A. D. Dreyfuss, et al.
Pubblicazione: (2025)

635 | SYMPTOM BURDEN AND HEALTH‐RELATED QUALITY OF LIFE IN PATIENTS WITH AGGRESSIVE NON‐HODGKIN LYMPHOMA IN CHINA: A CROSS‐SECTIONAL STUDY
di: J. Jin, et al.
Pubblicazione: (2025)

861 | BRIDGING RADIATION THERAPY IN CAR‐T THERAPY
di: T. Li, et al.
Pubblicazione: (2025)

512 | PROGNOSTIC VALUE OF BASELINE METABOLIC BIOMARKERS ASSESSED BY F18‐FDG PET/CT IN DIFFUSE LARGE B‐CELL LYMPHOMA
di: B. Chen, et al.
Pubblicazione: (2025)

650 | EFFICACY OF POLA‐R‐CHP IN PATIENTS WITH NEWLY DIAGNOSED DLBCL: A RETROSPECTIVE ANALYSIS OF REAL‐WORLD DATA
di: S. Yang, et al.
Pubblicazione: (2025)

636 | GLOFITAMAB COMBINED WITH SALVAGE THERAPY FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A REAL‐WORLD PROSPECTIVE OBSERVATIONAL STUDY IN CHINESE PATIENTS
di: H. Huang
Pubblicazione: (2025)

423 | ctDNA‐DIRECTED INTERVENTION WITH EPCORITAMAB ALONE OR IN COMBINATION WITH LENALIDOMIDE‐RITUXIMAB IS FEASIBLE IN THE EARLY POST‐CAR‐T POPULATION AT HIGH RISK OF RELAPSE
di: M. R. Dowling, et al.
Pubblicazione: (2025)

373 | PROGNOSTIC VALUE OF 18F‐FDG PET/CT VOLUMETRIC PARAMETERS IN CHILDHOOD, ADOLESCENT, AND YOUNG ADULT HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW FROM THE SEARCH GROUP
di: C. Gowdy, et al.
Pubblicazione: (2025)

508 | BAYESIAN PENALIZED LIKELIHOOD RECONSTRUCTION ALGORITHM RESULTS IN SIMILAR PROGNOSTIC MARKERS ON FDG PET/CT IN DLBCL
di: H. L. Huang, et al.
Pubblicazione: (2025)

484 | SINGLE‐CELL ANALYSIS OF CIRCULATING IMMUNE HETEROGENEITY IN DIFFUSE LARGE B‐CELL LYMPHOMA HIGHLIGHTS DISTINCT IMMUNE CELL SIGNATURES IN IMMUNOTHERAPY
di: S. Zhang, et al.
Pubblicazione: (2025)

ON08 | EDUCATIONAL NEEDS OF SWISS PATIENTS WITH HEMATOLOGICAL DISEASES: FOCUS ON KNOWLEDGE REGARDING HEMATOLOGY LABORATORY RESULTS AND BIOMEDICAL CONCEPTS
di: C. Dedieu, et al.
Pubblicazione: (2025)

Documenti analoghi

Documenti analoghi